

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Recce Pharmaceuticals Ltd ( <b>Company</b> )
<b>ABN</b>	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Alistair McKeough
<b>Date of last notice</b>	1 September 2022

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Finn Frist Pty Ltd as trustee for the AZM Superannuation Fund of which Mr McKeough is a director and shareholder of the trustee and a beneficiary of the trust ( <b>Finn Frist Pty Ltd</b> )  Amabel Pty Limited as trustee for the McKeough Family Trust of which Mr McKeough is a director of the trustee and a beneficiary of the trust ( <b>Amabel Pty Limited</b> )
<b>Date of change</b>	15 November 2022
<b>No. of securities held prior to change</b>	25,000 fully paid ordinary shares
<b>Class</b>	Unlisted options
<b>Number acquired</b>	1,125,000 unlisted options each exercisable as \$1.56, expiring 15 November 2027

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	The estimated value of per option is \$0.2777 based on a valuation undertaken by Pitcher Partners using the Black Scholes Model and the closing price of the Company's Shares on 29 September 2022 (\$0.74).
<b>No. of securities held after change</b>	Finn Frist Pty Ltd  1. 25,000 fully paid ordinary shares  Amabel Pty Limited  1. 1,125,000 unlisted options each exercisable as \$1.56, expiring 15 November 2027
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of options, as approved by shareholders at the Company's annual general meeting held on 14 November 2022.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

Interest after change	N/A
-----------------------	-----

**Part 3 – <sup>+</sup>Closed period**

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

<sup>+</sup> See chapter 19 for defined terms.